Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Deferred Taxes (2016 - 2024)

Historic Deferred Taxes for Myriad Genetics (MYGN) over the last 15 years, with Q4 2024 value amounting to $200000.0.

  • Myriad Genetics' Deferred Taxes rose 10869.57% to $200000.0 in Q4 2024 from the same period last year, while for Sep 2025 it was -$3.4 million, marking a year-over-year increase of 3584.91%. This contributed to the annual value of -$2.8 million for FY2024, which is 3000.0% up from last year.
  • Per Myriad Genetics' latest filing, its Deferred Taxes stood at $200000.0 for Q4 2024, which was up 10869.57% from -$1.4 million recorded in Q3 2024.
  • Myriad Genetics' Deferred Taxes' 5-year high stood at $49.0 million during Q2 2020, with a 5-year trough of -$48.4 million in Q3 2020.
  • For the 5-year period, Myriad Genetics' Deferred Taxes averaged around -$4.9 million, with its median value being -$2.2 million (2023).
  • In the last 5 years, Myriad Genetics' Deferred Taxes soared by 238571.43% in 2020 and then crashed by 166666.67% in 2022.
  • Quarter analysis of 5 years shows Myriad Genetics' Deferred Taxes stood at -$44.2 million in 2020, then soared by 90.27% to -$4.3 million in 2021, then crashed by 104.65% to -$8.8 million in 2022, then surged by 73.86% to -$2.3 million in 2023, then surged by 108.7% to $200000.0 in 2024.
  • Its last three reported values are $200000.0 in Q4 2024, -$1.4 million for Q3 2024, and -$2.2 million during Q2 2024.